Regulus Therapeutics Inc.
RGLSDelisted Jun 25, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001505512
Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.
13F holders, Q3 2025
Institutional positions in Regulus Therapeutics Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
RGLS is no longer listed, and 13F filings after Q1 2025 list far fewer holders. See Q1 2025
- Institutional holders
- 0
- −1 vs. Q2 2025
- Shares held
- 0
- 0 vs. Q2 2025
- Total value
- $0
- −$760 (−100.0%) vs. Q2 2025
- New holders
- 0
- 0 more added
- Sold out
- 1
- 0 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RGLS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $760 |
| Q1 2025 | 75 | $107.0M |
| Q4 2024 | 69 | $84.5M |
| Q3 2024 | 70 | $89.1M |
| Q2 2024 | 63 | $109.5M |
| Q1 2024 | 45 | $147.3M |
| Q4 2023 | 26 | $14.2M |
| Q3 2023 | 25 | $15.0M |
| Q2 2023 | 26 | $15.0M |
| Q1 2023 | 27 | $6.82M |
| Q4 2022 | 28 | $11.1M |
| Q3 2022 | 25 | $13.8M |
| Q2 2022 | 28 | $12.6M |
| Q1 2022 | 37 | $18.1M |
| Q4 2021 | 38 | $9.54M |
| Q3 2021 | 42 | $15.9M |
| Q2 2021 | 45 | $18.7M |
| Q1 2021 | 44 | $42.6M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Regulus Therapeutics Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| IFP Advisors, Inc | 0 | $0 | 0.00% | 0 | Sold out |